BioLight Life Sciences Ltd
BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company's ophthalmic product offering and pipeline of product candidates include DiagnosTear's TeaRx technology, a diagnostic platform for diagnosis of disease in the frontal areas of the eye through examination… Read more
Market Cap & Net Worth: BioLight Life Sciences Ltd (BOLT)
BioLight Life Sciences Ltd (TA:BOLT) has a market capitalization of $8.01 Million (ILA2.99 Billion) as of March 18, 2026. Listed on the TA stock exchange, this Israel-based company holds position #41411 globally and #385 in its home market, demonstrating a -4.62% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioLight Life Sciences Ltd's stock price ILA330.10 by its total outstanding shares 9047603 (9.05 Million).
BioLight Life Sciences Ltd Market Cap History: 2015 to 2026
BioLight Life Sciences Ltd's market capitalization history from 2015 to 2026. Data shows change from $74.53 Million to $8.00 Million (-20.01% CAGR).
BioLight Life Sciences Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioLight Life Sciences Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
60.92x
BioLight Life Sciences Ltd's market cap is 60.92 times its annual revenue
1742.66x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $74.53 Million | $1.39 Million | -$19.26 Million | 53.58x | N/A |
| 2016 | $30.80 Million | $2.11 Million | -$21.82 Million | 14.59x | N/A |
| 2017 | $35.33 Million | $1.21 Million | -$17.26 Million | 29.22x | N/A |
| 2018 | $30.39 Million | $3.69 Million | $65.39 Million | 8.24x | 0.46x |
| 2019 | $20.86 Million | $297.00K | -$12.59 Million | 70.24x | N/A |
| 2020 | $19.04 Million | $31.00K | -$13.38 Million | 614.23x | N/A |
| 2021 | $27.99 Million | $3.00K | $382.00K | 9330.59x | 73.28x |
| 2022 | $16.49 Million | $63.00K | -$7.85 Million | 261.81x | N/A |
| 2023 | $12.83 Million | $118.00K | -$26.02 Million | 108.74x | N/A |
| 2024 | $13.34 Million | $219.00K | -$7.14 Million | 60.92x | N/A |
Competitor Companies of BOLT by Market Capitalization
Companies near BioLight Life Sciences Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to BioLight Life Sciences Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
BioLight Life Sciences Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, BioLight Life Sciences Ltd's market cap moved from $74.53 Million to $ 8.00 Million, with a yearly change of -20.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA8.00 Million | -4.26% |
| 2025 | ILA8.36 Million | -37.33% |
| 2024 | ILA13.34 Million | +3.97% |
| 2023 | ILA12.83 Million | -22.21% |
| 2022 | ILA16.49 Million | -41.07% |
| 2021 | ILA27.99 Million | +47.01% |
| 2020 | ILA19.04 Million | -8.72% |
| 2019 | ILA20.86 Million | -31.36% |
| 2018 | ILA30.39 Million | -13.98% |
| 2017 | ILA35.33 Million | +14.73% |
| 2016 | ILA30.80 Million | -58.68% |
| 2015 | ILA74.53 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of BioLight Life Sciences Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.01 Million USD |
| MoneyControl | $8.01 Million USD |
| MarketWatch | $8.01 Million USD |
| marketcap.company | $8.01 Million USD |
| Reuters | $8.01 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.